Updated Monday, 11/16. US IPO market activity is picking back up ahead of the Thanksgiving holiday, with seven IPOs scheduled to raise $3.6 billion in the week ahead. Biotech research product provider ...read more
Five IPOs and 17 SPACs went public this past week. While new filing activity has slowed as the election approaches, four IPOs and four SPACs submitted initial filings. Leading security software provider McAfee (MCFE) priced...read more
Foghorn Therapeutics, a preclinical biotech developing gene therapies for hematologic cancers and solid tumors, raised $120 million by offering 7.5 million shares at $16, within the range of $15 to $17. At pricing, the company commands a fully diluted market...read more
Foghorn Therapeutics, a preclinical biotech developing gene therapies for hematologic cancers and solid tumors, announced terms for its IPO on Monday. The Cambridge, MA-based company plans to raise $120 million by offering 7.5 million shares at a price...read more
US IPO Week Ahead: 7 IPOs squeeze in before the Thanksgiving holiday
Updated Monday, 11/16. US IPO market activity is picking back up ahead of the Thanksgiving holiday, with seven IPOs scheduled to raise $3.6 billion in the week ahead. Biotech research product provider ...read more
US IPO Weekly Recap: McAfee leads a 5 IPO week
Five IPOs and 17 SPACs went public this past week. While new filing activity has slowed as the election approaches, four IPOs and four SPACs submitted initial filings. Leading security software provider McAfee (MCFE) priced...read more
Preclinical oncology biotech Foghorn Therapeutics prices IPO at $16 midpoint
Foghorn Therapeutics, a preclinical biotech developing gene therapies for hematologic cancers and solid tumors, raised $120 million by offering 7.5 million shares at $16, within the range of $15 to $17. At pricing, the company commands a fully diluted market...read more
Preclinical oncology biotech Foghorn Therapeutics sets terms for $120 million IPO
Foghorn Therapeutics, a preclinical biotech developing gene therapies for hematologic cancers and solid tumors, announced terms for its IPO on Monday. The Cambridge, MA-based company plans to raise $120 million by offering 7.5 million shares at a price...read more